Skip to content

Envoy Medical COCH Sale of stock, price per share (in dollars per share)

Sale of stock, price per share (in dollars per share) at other companies

Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$0.01
BillionToOne, Inc.
 logo
BillionToOne, Inc. BLLN
$60.00
electroCore, Inc. logo
electroCore, Inc.ECOR
$6.62
SKYX Platforms Corp. logo
SKYX Platforms Corp.SKYX
$1.20
CBAK Energy Technology, Inc. logo
CBAK Energy Technology, Inc.CBAT
$5.18
New America Acquisition I
 logo
New America Acquisition I NWAX
$10.00

Other financials

Income statement

See full
Revenue$39.0K-15.2%
Gross profit-$274.0K-52.2%
Operating income-$6.0M-16.7%
Net income-$4.4M+12.9%
EPS (diluted)-$0.08+72.4%

Balance sheet

See full
Cash & equivalents$25.3M+376%
Total debt$919.0K-2.8%
Total equity$10.2M+142%
Total assets$29.8M+187%

Cash flow

See full
Operating cash flow-$6.1M-62.7%
CapEx$172.0K
Free cash flow-$5.9M-28.5%

Valuation

See full
Market cap$61M+83.5%
P/S260.7×+111×

Profitability

See full
Gross margin-310.7%+31.6pp
Operating margin-9,881.2%+805pp
Net margin-9,875.6%+771pp
FCF margin-7,626.6%-652pp

Returns & leverage

See full
Return on equity328.7%
Debt / equity0.1×
Current ratio2.3×+1.2×

Where this comes from

Reported directly by Envoy Medical in its filing.

Tagged under the XBRL concept us-gaap:SaleOfStockPricePerShare.

The official record: Envoy Medical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Envoy Medical's sale of stock, price per share (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Envoy Medical's sale of stock, price per share (in dollars per share)?
Envoy Medical (COCH) reported sale of stock, price per share (in dollars per share) of $4.00 in Q4 2024.
What does sale of stock, price per share (in dollars per share) mean?
The average price at which the company issued shares during a specific period. This metric provides insight into the market's valuation of the company at the time of capital raises and the dilution impact on existing shareholders. Comparing this to current market prices helps investors evaluate the efficiency of the company's capital-raising activities.